Comparative Biosciences Inc.

# CBI News



**The Reliable Resource for the Biomedical Community**

**September 2011**

*CBI welcomes back*

*Taylor Norwitt as Senior Sales Representative*

*email: taylor_norwitt@compbio.com phone: 408.504.8871*

::::::::::::

## Models of MS: EAE models in mice

CBI offers a number of robust validated models of experimental allergic encephalitis (EAE) in mice and small animals. These include MOG-induced, PLP-induced, and cuprizone induced models. In a typical study, following induction, daily clinical changes, lameness, body weights, food consumption and other parameters are assessed. Necropsy and histopathology includes detailed CNS assessments with options for immunohistochemistry and image analysis as well as in vitro tests.

### MOG-Induced EAE in C57BL/6 mice

CBI has validated in a chronic progressive EAE model in C57BL/6 mice. Dexamethasone, interferon and copaxone have demonstrated to be effective positive control Dexamethasone is effective either prophylactically or therapeutically. Administration of myelin oligodendrocyte glycoprotein 35-55 (MOG35-55) induces clinical lameness and histologic lesions characteristic of progressive chronic disease including limp tail, weakness of the hind and/or front legs and complete paralysis. Histologically, there is loss of myelin and inflammation of the neuropil.

**Featured Histology Capabilities at CBI**

Assessment of neural degeneration and apoptosis in neonatal brains of primates and smaller laboratory animals treated with ketamine

Apoptosis and neural degeneration stains

- Activated Caspase
- TUNEL
- Fluoro Jade
- Silver Stains
- GFAP

**For more information, contact Mike Zamora**
**mike_zamora@compbio.com**

::::

### Stem Cell Initiative

CIRM appoints new director. Jonathan Thomas Succeeds Robert Klein as CIRM Board Chair. The Governing Board of the California Institute for Regenerative Medicine, the state stem cell agency created by proposition 71, today approved the concept for a $30 million initiative that is intended to make the agency more nimble in seizing emerging opportunities in the rapidly

evolving field. It appears that CIRM has committed nearly $1B in research funding, primarily to academic labs, and fewer biotech companies recently and is now seeking more funds to support this important area of research.










**Quick Links**

**Contact Us**
**Our Website**
**About CBI**

Join Our Mailing List!

**Comparative Biosciences, Inc.**
**786 Lucerne Drive**
**Sunnyvale, CA 94085**

**Phone: 408.738.9260**
**Fax: 408.738.9278**

**For information on pre-clinical ophthalmic pharmacokinetics, efficacy modeling and toxicology services offered at CBI, contact Mike Zamora, Business Development Manager**

**Tel: 408.738.9265**
**Email: mike_zamora@compbio.com**